Get started
Author

Farhad Sahebkar

Observed names: F. Sahebkar, F. Sahebkar-Moghaddam, Farhad Sahebkar-Moghaddam, Farhad Sahebkar-moghaddam
Observed institutions: Sutter Health, Amgen (United States), Witten/Herdecke University, University of California, San Francisco, California Pacific Medical Center, Jazz Pharmaceuticals (United States), University Children's Hospital Zurich, Stanford Medicine, Greenwich Biosciences (United States), Stanford University
ORCID: 0000-0002-7748-7836
Observed ORCID: 0000-0002-7748-7836
OpenAlex ID: A5008258554
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex
2020 · Elizabeth A. Thiele, E. Martina Bebin, et al. · JAMA Neurology · 289
PDF
Long‐term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: An open‐label extension trial
2021 · Elizabeth A. Thiele, E. Martina Bebin, et al. · Epilepsia · 115
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
2019 · Bola Tayo, Lesley Taylor, et al. · Clinical Pharmacokinetics · 66
PDF
Early prediction of neurologic outcome after perinatal depression
1999 · Beatrice Latal Hajnal, Farhad Sahebkar-Moghaddam, et al. · Pediatric Neurology · 57
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6
2022 · Joyce Y. Wu, Hannah R. Cock, et al. · Epilepsia · 51
PDF
Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant epilepsies: Four‐year results from the expanded access program
2022 · Jerzy P. Szaflarski, Orrin Devinsky, et al. · Epilepsia · 36
PDF
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures
2021 · Martin J. Brodie, Piotr Czapinski, et al. · Cannabis and Cannabinoid Research · 31
Efficacy of cannabidiol in convulsive and nonconvulsive seizure types associated with treatment‐resistant epilepsies in the Expanded Access Program
2023 · Robert J. Flamini, Anne M. Comi, et al. · Epilepsia · 20
PDF
Seizure‐free days as a novel outcome in patients with Lennox–Gastaut syndrome: Post hoc analysis of patients receiving cannabidiol in two randomized controlled trials
2023 · Stéphane Auvin, Charlotte Nortvedt, et al. · Epilepsia · 18
PDF
Rhomb- and Bickerstaff Encephalitis: Two Clinical Phenotypes?
2013 · Rebecca C. Gologorsky, Jerome A. Barakos, et al. · Pediatric Neurology · 11
Long‐term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3‐year results from the cannabidiol expanded access program
2024 · Arie Weinstock, E. Martina Bebin, et al. · Epilepsia Open · 8
PDF
The failed lumbar puncture
2005 · F. Sahebkar-Moghaddam, B. T. Adornato · Neurology · 7
Long-term Efficacy and Safety of Cannabidiol (CBD) in Patients with Tuberous Sclerosis Complex (TSC): 4-year Results from the Expanded Access Program (EAP) (2405)
2021 · Arie Weinstock, E. Martina Bebin, et al. · Neurology · 6
Time to Onset of Cannabidiol (CBD) Treatment Effect and Resolution of Adverse Events (AEs) in the Tuberous Sclerosis Complex (TSC) Phase 3 Randomized Controlled Trial (GWPCARE6) (674)
2020 · Joyce Wu, Hannah Cock, et al. · Neurology · 6
Erenumab Immunogenicity: a Pooled Analysis of Phase 2 and Phase 3 Migraine Prevention Clinical Trials (P4.098)
2018 · Bert Vargas, Amaal Starling, et al. · Neurology · 6
Long-term Safety and Efficacy of Cannabidiol (CBD) for the Treatment of Seizures in Patients with Tuberous Sclerosis Complex (TSC) in an Open-label Extension (OLE) Trial (GWPCARE6) (677)
2020 · Elizabeth Thiele, E Martina Bebin, et al. · Neurology · 5
The failed lumbar puncture
2005 · Farhad Sahebkar-Moghaddam, Bruce T. Adornato · Neurology · 5
PDF
Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Treatment of Seizures Associated with Tuberous Sclerosis Complex (TSC) in an Open-Label Extension (OLE) Trial (GWPCARE6) (1127)
2021 · James Wheless, E. Martina Bebin, et al. · Neurology · 4
Long-term Safety and Efficacy of Add-on Cannabidiol (CBD) for Seizures Associated With Tuberous Sclerosis Complex (TSC): 3-Year Results From GWPCARE6 Open-Label Extension (OLE) (P14-1.004)
2023 · Elizabeth Thiele, E. Martina Bebin, et al. · Neurology · 2
Efficacy of Add-on Cannabidiol (CBD) Treatment in Patients with Tuberous Sclerosis Complex (TSC) and a History of Infantile Spasms (IS): Post Hoc Analysis of Phase 3 Trial GWPCARE6 (1534)
2021 · Russell Saneto, Steven Sparagana, et al. · Neurology · 2
Early Prediction of Neurologic Outcome After Perinatal Depression
2000 · Beatrice Latal Hajnal, Farhad Sahebkar-Moghaddam, et al. · Obstetrical & Gynecological Survey · 2
Long-term Effectiveness of Cannabidiol (CBD) Against Focal-onset Seizures in Treatment-resistant Epilepsies (TRE): Experience from the Expanded Access Program (EAP) (S29.005)
2024 · Yong Park, Karthik Rajasekaran, et al. · Neurology · 1
Cannabidiol Efficacy in Patients with Lennox-Gastaut Syndrome with Developmental and Epileptic Encephalopathy-associated Genetic Variants: A Subgroup Analysis (P10-10.008)
2026 · Elizabeth A. Thiele, Michael Boffa, et al. · Neurology
Real-world Safety and Effectiveness of Cannabidiol (CBD) in Adults with Treatment-resistant Epilepsies (TREs): Long-term Results from the United States Expanded Access Program (EAP) (P8-1.002)
2024 · Jerzy Szaflarski, Timothy Saurer, et al. · Neurology
Long-term safety and efficacy of add-on cannabidiol (CBD) for seizures associated with tuberous sclerosis complex (TSC): 3-year results from GWPCARE6 open-label extension (OLE)
2023 · James Wheless, Elizabeth A. Thiele, et al. · Journal of the Neurological Sciences
PDF
Works count: 30
Citation count: 748
H-index: 10
I10-index: 10
Year
Topic
Type